Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Cited by (1,010)

Items 301–400 of 1,010

1. Exercise reduces immune suppression and breast cancer progression in a preclinical model
   Erik Wennerberg, Claire Lhuillier, Marissa Danielle Rybstein, Kyle Dannenberg, Nils-Petter Rudqvist, Graeme J. Koelwyn, Lee W. Jones, Sandra Demaria · 2020 · Oncotarget
2. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
   Dominik Głodzik, Ana Bosch, Johan Hartman, Mattias Aine, Johan Vallon‐Christersson, Christel Reuterswärd, Anna Karlsson, Shamik Mitra, Emma Niméus, Karolina Holm et al. · 2020 · Nature Communications
3. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
   Yutian Zou, Xuxiazi Zou, Shaoquan Zheng, Hailin Tang, Lijuan Zhang, Peng Liu, Xiaoming Xie · 2020 · Therapeutic Advances in Medical Oncology
4. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
   Sara M. Tolaney, Kevin M. Kalinsky, Virginia Kaklamani, David R. D’Adamo, Gursel Aktan, Michaela L. Tsai, Ruth M O'Regan, Peter Andrew Kaufman, Sharon T. Wilks, Eleni Andreopoulou et al. · 2021 · Clinical Cancer Research
5. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
   Arielle Lutterman Heeke, Antoinette R. Tan · 2021 · Cancer and Metastasis Reviews
6. Immunotherapy for early breast cancer: too soon, too superficial, or just right?
   Maria Alice Franzoi, Emanuela Romano, Martine J Piccart · 2020 · Annals of Oncology
7. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
   Enrico Munari, Francesca Romana Mariotti, Linda Quatrini, Pietro Bertoglio, Nicola Tumino, Paola Vacca, Albino Eccher, Francesco Ciompi, Matteo Brunelli, Guido Martignoni et al. · 2021 · International Journal of Molecular Sciences
8. Vitamin E enhances cancer immunotherapy by reinvigorating dendritic cells via targeting checkpoint SHP1.
   Yuan, Xiangliang, Duan, Yimin, Xiao, Yi, Sun, Kai, Qi, Yutao, Zhang, Yuan, Ahmed, Zamal, Moiani, Davide, Yao, Jun, Li, Hongzhong et al. · 2022 · Cancer Discovery
9. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
   Xiaoqing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuanyu Fang, Chenglong Li, Yi‐Zhou Jiang, Shuai Wang, Hongyu Zhao, Jingya Miao et al. · 2023 · Cell Research
10. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
    David M. Goldenberg, Robert M. Sharkey · 2020 · Expert Opinion on Biological Therapy
11. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
    Hannah Noelle Bell, Weiping Zou · 2024 · Annual Review of Immunology
12. Clinical applications of nanomedicine in cancer therapy
    Mohammad Norouzi, Mehrnaz Amerian, Mahshid Amerian, Fatemeh Atyabi · 2019 · Drug Discovery Today
13. HER2-positive advanced breast cancer treatment in 2020
    Marcelle Goldner Cesca, Lucas Vian, Sofia Cristóvão‐Ferreira, Noam Falbel Ponde, Evandro de Azambuja · 2020 · Cancer Treatment Reviews
14. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
    Carlos Gomez‐Roca, Philippe Alexandre Cassier, Dmitriy Zamarin, Jean‐Pascal Machiels, José Luis Perez‐Gracia, Frank Stephen Hodi, Álvaro Taus, Maria Martinez‐García, Valentina Boni, Joseph P. Eder et al. · 2022 · Journal for ImmunoTherapy of Cancer
15. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
    Mariya Rozenblit, Richard S.P. Huang, Natalie A. Danziger, Priti S. Hegde, Brian Michael Alexander, Shakti H Ramkissoon, Kim Blenman, Jeffrey S. Ross, David L. Rimm, Lajos Pusztai · 2020 · Journal for ImmunoTherapy of Cancer
16. Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
    Krupa Naran, Trishana Nundalall, Shivan Chetty, Stefan Barth · 2018 · Frontiers in Microbiology
17. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
    Daniel R. Principe, Matthew Narbutis, Sandeep Kumar, Alex J. Park, Navin Viswakarma, Matthew J. Dorman, Suneel Deepak Kamath, Paul J. Grippo, Melissa L. Fishel, Rosa F. Hwang et al. · 2020 · Cancer Research
18. Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death
    Kun Tu, Huan Deng, Li Kong, Yi Wang, Ting Yang, Qian Hu, Mei Ying Hu, Conglian Yang, Zhiping Zhang · 2020 · ACS Applied Materials & Interfaces
19. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
    Stefania Cocco, Michela Piezzo, Alessandra Calabrese, Daniela Cianniello, Roberta Caputo, Vincenzo Di Lauro, Giuseppina Fusco, Germira Di Gioia, Marina Licenziato, Michelino De Laurentiis · 2020 · International Journal of Molecular Sciences
20. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer
    Xinyun Qiu, Yan Qu, Beibei Guo, Huan Zheng, Fenghua Meng, Zhiyuan Zhong · 2021 · Journal of Controlled Release
21. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials
    Fang Yang, Svetomir N. Markovic, Julian R. Molina, Thorvardur Ragnar Halfdanarson, Lance C. Pagliaro, Ashish Vittalrao Chintakuntlawar, Rutian Li, Jia Wei, Lifeng Wang, Baorui Liu et al. · 2020 · JAMA Network Open
22. Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
    Qi-Yao Wei, Yan‐Ming Xu, Andy T. Y. Lau · 2020 · Cancers
23. Immune checkpoint inhibitors win the 2018 Nobel Prize
    Pei‐Wei Huang, John Wen‐Cheng Chang · 2019 · Biomedical Journal
24. Tumor mutational burden as a predictor of immunotherapy response in breast cancer
    Tess A. O’Meara, Sara M. Tolaney · 2021 · Oncotarget
25. How I treat cancer-associated anemia
    Jeffrey A. Gilreath, George M. Rodgers · 2020 · Blood
26. Predictive biomarkers for response to immune checkpoint inhibition
    Benjamin Shum, James Larkin, Samra Turajlic · 2021 · Seminars in Cancer Biology
27. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
    Chuyu Jing, Yi‐Peng Fu, Yong Yi, Meixia Zhang, Su-Su Zheng, Jinlong Huang, Wei Gan, Xin Xu, Jiajia Lin, Juan Zhang et al. · 2019 · Journal for ImmunoTherapy of Cancer
28. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer
    Molly A. Nelson, Worapol Ngamcherdtrakul, Shiuh-Wen Luoh, W. Yantasee · 2021 · Cancer Metastasis Review
29. Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer
    Di Huang, Xueman Chen, Xin Zeng, Liyan Lao, Jiaqian Li, Yue Xing, Yiwen Lu, Qian Ouyang, Jianing Chen, Linbin Yang et al. · 2021 · Nature Immunology
30. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
    Susana García‐Recio, Toshinori Hinoue, Gregory L. Wheeler, Benjamin Kelly, Ana Christina Garrido-Castro, Tomás Pascual, Aguirre A. de Cubas, Youli Xia, Brooke Felsheim, Marni B. McClure et al. · 2022 · Nature Cancer
31. 3D approaches to model the tumor microenvironment of pancreatic cancer
    Elena Tomás Bort, Markus Kieler, Shreya Sharma, Juliana B. Candido, Daniela Loessner · 2020 · Theranostics
32. Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
    Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng · 2021 · Frontiers in Oncology
33. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy
    Xu Cao, Jing Chen, Bolei Li, Jessica Dang, Wencan Zhang, Xiancai Zhong, Chongkai Wang, Mustafa Raoof, Zuoming Sun, Jianhua Yu et al. · 2022 · Science Advances
34. Targeting Autophagy in Breast Cancer
    Stefania Cocco, Alessandra Leone, Michela Piezzo, Roberta Caputo, Vincenzo Di Lauro, Francesca Di Rella, Giuseppina Fusco, Monica Capozzi, Germira Di Gioia, Alfredo Budillon et al. · 2020 · International Journal of Molecular Sciences
35. Combinatorial therapy in tumor microenvironment: Where do we stand?
    Smita Kumari, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta, Pravir Kumar · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
36. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer
    Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Liping Ye, Chengming Zhu, Liang Deng, Bo Wang, Yihang Pan, Peng Li · 2022 · Breast Cancer Research
37. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
    Lei Zhang, Han Zheng, Shitao Jiang, Yao-Ge Liu, Ting Zhang, Junwei Zhang, Xin Lü, Haitao Zhao, Xinting Sang, Yiyao Xu · 2024 · International Journal of Surgery
38. Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
    Nicholas Patrick McAndrew, Richard S. Finn · 2021 · JCO Oncology Practice
39. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
    Alexios Matikas, Ioannis Zerdes, John Lövrot, François Richard, Christos P. Sotiriou, Jonas C. S. Bergh, Antonios Valachis, Theodoros Foukakis · 2019 · Clinical Cancer Research
40. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
    Alexandra S. Zimmer, E. Hitt Nichols, Ashley Cimino‐Mathews, Cody J. Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel et al. · 2019 · Journal for ImmunoTherapy of Cancer
41. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis
    Wenfa Huang, Ran Ran, Bin Shao, Huiping Li · 2019 · Breast Cancer Research and Treatment
42. Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
    Katherine E. Hutchinson, Susan Elaine Yost, Ching‐Wei Chang, Radia Marie Johnson, Adrian R. Carr, Paul R. McAdam, Daniel L. Halligan, Chun-Chieh Chang, Daniel B. Schmolze, Jackson Liang et al. · 2019 · Clinical Cancer Research
43. Role of Tumor-Associated Myeloid Cells in Breast Cancer
    Yoon Jin Cha, Ja Seung Koo · 2020 · Cells
44. Tumor-Targeted Nanomedicine for Immunotherapy
    Horacio Cabral, Hiroaki Kinoh, Kazunori Kataoka · 2020 · Accounts of Chemical Research
45. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models
    Myrofora Panagi, Fotios Mpekris, Pengwen Chen, Chrysovalantis Voutouri, Yasuhiro Nakagawa, John D. Martin, Tetsuro Hiroi, Hiroko Hashimoto, Philippos Demetriou, Chryso Pierides et al. · 2022 · Nature Communications
46. The complementarity of DDR, nucleic acids and anti-tumour immunity
    Anand V. R. Kornepati, Cody M. Rogers, Patrick Sung, Tyler Jay Curiel · 2023 · Nature
47. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
    Shira Yomtoubian, Sharrell B. Lee, Akanksha Verma, Franco Izzo, Geoffrey J. Markowitz, Hyejin Choi, Leandro C. A. Cerchietti, Linda T. Vahdat, Kristy A. Brown, Eleni Andreopoulou et al. · 2020 · Cell Reports
48. Microscaled proteogenomic methods for precision oncology
    Shankha Satpathy, Eric J. Jaehnig, Karsten Krug, Beom‐Jun Kim, Alexander B. Saltzman, Doug W. Chan, Kimberly R. Holloway, Meenakshi Anurag, Chen Lu Huang, Purba Singh et al. · 2020 · Nature Communications
49. PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis
    Fatmah A. Mansour, Amer Al‐Mazrou, Falah Almohanna, Monther M Al-Alwan, Hazem Ghebeh · 2020 · OncoImmunology
50. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases
    Richard S.P. Huang, James Haberberger, Eric Allan Severson, Daniel L. Duncan, Amanda C. Hemmerich, Claire I. Edgerly, N. Lynn Ferguson, Erik Abraham Williams, Julia Andrea Elvin, Jo‐Anne Vergilio et al. · 2020 · Modern Pathology
51. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review
    Guillermo Valdivia, Ángela Alonso‐Diez, María Dolores Pérez Alenza, L. Peña · 2021 · Frontiers in Veterinary Science
52. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
    Liying Li, Fan Zhang, Zhenyu Liu, Zhimin Fan · 2023 · Cancers
53. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
    Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin, Lisa Belin, Katharina Leitner, David Cibula, Hannelore G Denys, Ora Solange Rosengarten, Manuel Jorge Rodrigues, Nikolaus de Gregorio et al. · 2023 · Journal of Clinical Oncology
54. The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
    Adrienne Gropper Waks, Daniel G. Stover, Jennifer L. Guerriero, Deborah A. R. Dillon, William Thomas Barry, Evisa Gjini, Christina Hartl, Wesley Lo, Jennifer Savoie, Jane E. Brock et al. · 2019 · Clinical Cancer Research
55. PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression
    Shuo Deng, H. C. Leong, A. Datta, Vennila Gopal, A. Kumar, C. Yap · 2022 · Cancers
56. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
    Jacques L. Cadranel, Anthony Canellas, Lise Matton, Marie Darrason, A. Parrot, Jean‐Marc Naccache, A. Lavolé, Anne-Marie Ruppert, Vincent Fallet · 2019 · European Respiratory Review
57. Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers
    Tian‐Jian Yu, Ding Ma, Yingying Liu, Yi Xiao, Yue Gong, Yi‐Zhou Jiang, Zhi-Ming Shao, Xin Hu, Gen‐Hong Di · 2021 · Molecular Therapy
58. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study
    Janis Marie Taube, Kristin Roman, Elizabeth L. Engle, Chichung Wang, Carmen Ballesteros‐Merino, Shawn M. Jensen, John McGuire, Mei Jiang, Carla Coltharp, Bethany Remeniuk et al. · 2021 · Journal for ImmunoTherapy of Cancer
59. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
    Yiling Wang, Audrey Minden · 2022 · International Journal of Molecular Sciences
60. Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy
    Heya Lin, Wei Guo Xiong, Lili Fu, Jie Yi, Jiantang Yang · 2025 · Molecular Biomedicine
61. Atezolizumab for the treatment of triple-negative breast cancer
    Anne-Sophie Heimes, Marcus Schmidt · 2018 · Expert Opinion on Investigational Drugs
62. Cancer cell-intrinsic mechanisms driving acquired immune tolerance
    Ehsan Ghorani, Charles Swanton, Sergio A. Quezada · 2023 · Immunity
63. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
    Javier Cortés, Kevin Punie, Carlos H. Barrios, Sara Alsterlind Hurvitz, Andreas Schneeweiß, Joohyuk Sohn, Eriko Tokunaga, Adam Brufsky, Yeon Hee Park, Binghe Xu et al. · 2025 · New England Journal of Medicine
64. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
    Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, Luigi Formisano, Roberto Bianco · 2020 · Journal of Clinical Medicine
65. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity
    Zhou, Zhuolong, Van der Jeught, Kevin, Fang, Yuanzhang, Yu, Tao, Li, Yujing, Ao, Zheng, Liu, Sheng, Zhang, Lu, Yang, Yang, Eyvani, Haniyeh et al. · 2021 · Nature Biomedical Engineering
66. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
    Elisa Agostinetto, Agnese Losurdo, Guilherme Nader Marta, Armando Santoro, Kevin Punie, Romualdo Barroso‐Sousa, LAZAR S. POPOVIC, Cinzia Solinas, Marleen Kok, Evandro de Azambuja et al. · 2022 · Expert Opinion on Investigational Drugs
67. Triple negative breast cancer: approved treatment options and their mechanisms of action
    Aditya Mandapati, Kiven Erique Lukong · 2022 · Journal of Cancer Research and Clinical Oncology
68. Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma
    Payal Deepak Shah, Alexander Chan Chi Huang, Xiaowei Xu, Robert J. Orlowski, Ravi K. Amaravadi, Lynn Mara Schuchter, Paul J. Zhang, Julia C. Tchou, Tina Matlawski, Amanda Cervini et al. · 2023 · Cancer Research Communications
69. Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy
    Saber İmani, Reyhaneh Farghadani, Ghazaal Roozitalab, Mazaher Maghsoudloo, Mahdieh Emadi, Atefeh Moradi, Behnaz Abedi, Parham Jabbarzadeh Kaboli · 2025 · Journal of Experimental & Clinical Cancer Research
70. Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control
    Meenakshi Sudhakaran, Sagar D. Sardesai, Andrea I. Doseff · 2019 · Antioxidants
71. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
    Ami N. Shah, Lisa Flaum, Irene Helenowski, Cesar Augusto Santa-Maria, Sarika Jain, ALFRED W. RADEMAKER, Valerie M. Nelson, Dean Tsarwhas, Massimo Cristofanilli, William John Gradishar · 2020 · Journal for ImmunoTherapy of Cancer
72. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
    Li Chen, Yi‐Zhou Jiang, Song‐Yang Wu, Jiong Wu, Gen‐Hong Di, Guang‐Yu Liu, Ke‐Da Yu, Lei Fan, Junjie Li, Yifeng Hou et al. · 2022 · Clinical Cancer Research
73. Sex and Gender Influences on Cancer Immunotherapy Response
    Azzurra Irelli, Maria Maddalena Sirufo, Carlo D’Ugo, Lia Ginaldi, Massimo De Martinis · 2020 · Biomedicines
74. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
    Nina Ditsch, Cornelia Kolberg‐Liedtke, Michael Friedrich, Christian Jackisch, Ute‐Susann Albert, Maggie Banys‐Paluchowski, Ingo Bauerfeind, Jens‐Uwe Blohmer, Wilfried Budach, Peter Dall et al. · 2021 · Breast Care
75. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
    Qiuhua Luo, Ling Zhang, Cong Luo, Mingyan Jiang · 2019 · Cancer Letters
76. CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells
    Sushil Kumar, Zexian Zeng, Archis Bagati, Rong En Tay, Lionel A. Sanz, Stella R. Hartono, Yoshinaga Ito, Fieda O. Abderazzaq, Elodie Hatchi, Peng Jiang et al. · 2021 · Cancer Discovery
77. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
    Samuel Aaron Funt, Michael William Lattanzi, Karissa A. Whiting, Hikmat A Al‐Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung‐Han Lee, David Henry Aggen, Danielle Elise Zimmerman, Deaglan Joseph McHugh et al. · 2022 · Journal of Clinical Oncology
78. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
    Soundararajan, Rama, Fradette, Jared, Konen, Jessica, Moulder, Stacy, Zhang, Xiang, Gibbons, Don, Varadarajan, Navin, Wistuba, Ignacio, Tripathy, Debasish, Bernatchez, Chantale et al. · 2019 · Cancers
79. Harnessing cancer immunotherapy during the unexploited immediate perioperative period
    Pini Matzner, Elad Sandbank, Elad Neeman, Oded Zmora, Vijaya N. R. Gottumukkala, Shamgar Ben‐Eliyahu · 2020 · Nature Reviews Clinical Oncology
80. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
    Fahad Shabbir Ahmed, Patricia Gaule, John McGuire, Katir Patel, Kim Blenman, Lajos Pusztai, David L. Rimm · 2020 · Clinical Cancer Research
81. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano‐immunotherapy in Breast Cancer Lung Metastasis
    Fotios Mpekris, Myrofora Panagi, Chrysovalantis Voutouri, John D. Martin, Rekha Samuel, Shinichiro Takahashi, Naoto Gotohda, Toshiyuki Suzuki, Panagiotis Papageorgis, Philippos Demetriou et al. · 2020 · Advanced Science
82. From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
    Madiha Saeed, Fang‐Ming Chen, Jiayi Ye, Yang Shi, Twan Lammers, Bruno G. De Geest, Zhi Ping Xu, Haijun Yu · 2021 · Advanced Materials
83. New emerging targets in cancer immunotherapy: the role of TIM3
    Alex Friedlaender, Alfredo Addeo, Giuseppe Luigi Banna · 2019 · ESMO Open
84. Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
    Karan Mediratta, Sara El‐Sahli, Vanessa M. D’Costa, Lisheng Wang · 2020 · Cancers
85. Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
    Mariacarmela Santarpía, Andrés Aguilar, Imane CHAIB-OUKADOUR, Andrés Felipe Cardona, Sara Fancelli, Fernando Laguía, Jillian Wilhelmina Paulina Bracht, Peng Cao, Miguel Ángel Molina‐Vila, Niki Karachaliou et al. · 2020 · Cancers
86. Targeting brain metastases in breast cancer
    Chiara Corti, Gabriele Antonarelli, Carmen Criscitiello, NU Lin, LA Carey, Javier Cortés, Philip M. Poortmans, Giuseppe Curigliano · 2021 · Cancer Treatment Reviews
87. The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities
    Hussein Sabit, Amro Adel, Mariam M. Abdelfattah, Rehab M. Ramadan, Mahmoud Nazih, Shaimaa E. Abdel-Ghany, Ahmed H. K. El-Hashash, Borros Arneth · 2025 · Cancer Letters
88. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
    Ajeeth Kumar Pingili, Mehdi Chaib, Laura M. Sipe, Emily J. Miller, Bin Teng, Rahul Sharma, Johnathan R. Yarbro, Sarah Asemota, Qusai Al Abdallah, Tahliyah S. Mims et al. · 2021 · Cell Reports
89. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer
    Farhan Sachal Cyprian, Saghir Akhtar, Zoran Gatalica, Semir Vranić · 2019 · Bosnian Journal of Basic Medical Sciences
90. Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer
    Haonan Li, Fanxing Xu, Gang Gao, Xiang Gao, Bo Wu, Chao Zheng, Peng Wang, Zhan‐Lin Li, Huiming Hua, Dahong Li · 2020 · Redox Biology
91. Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives
    Yang Shi · 2020 · Advanced Therapeutics
92. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
    Roberto Antonio Leon-Ferre, Tina J. Hieken, Judy Caroline Boughey · 2021 · Annals of Surgical Oncology
93. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities
    Laura M. Spring, Erika Nakajima, Jennifer A. Hutchinson, Elene Viscosi, Gayle C. Blouin, Colin D. Weekes, Hope S. Rugo, Beverly Moy, Aditya Bardia · 2021 · The Oncologist
94. Immunotherapy: an alternative promising therapeutic approach against cancers
    Sneh Lata Gupta, Srijani Basu, Vijay Soni, Rishi Kumar Jaiswal · 2022 · Molecular Biology Reports
95. Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
    Md Abdus Subhan, Farzana Parveen, Hassan Shah, Satya Siva Kishan Yalamarty, Janaína Artem Ataide, Valdimir P. Torchilin · 2023 · Cancers
96. How I treat metastatic triple-negative breast cancer
    Rafael Caparica, Matteo Lambertini, Evandro de Azambuja · 2019 · ESMO Open
97. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
    Ioannis Zerdes, Majken Wallerius, Emmanouil G. Sifakis, Tatjana Wallmann, Stina Betts, Margarita Bartish, Nikolaos Tsesmetzis, Nicholas P. Tobin, Christos Coucoravas, Jonas C. S. Bergh et al. · 2019 · Cancers
98. EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
    Lin Xia, Zaozao Zheng, Jun‐yi Liu, Yu‐jie Chen, Jian‐cheng Ding, Ningshao Xia, Wenxin Luo, Wen Liu · 2020 · Clinical & Translational Immunology
99. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
    Anne Y. Lai, Jessica A. Sorrentino, Konstantin H. Dragnev, Jared Weiss, Taofeek Kunle Owonikoko, Julie A. Rytlewski, Jill Van Wart Hood, Yang Zhao, Rajesh K. Malik, Jay C. Strum et al. · 2020 · Journal for ImmunoTherapy of Cancer
100. KAT6A Acetylation of SMAD3 Regulates Myeloid‐Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple‐Negative Breast Cancer
     Bo Yu, Fei Luo, Bowen Sun, Wenxue Liu, Qiqi Shi, Shi‐Yuan Cheng, Ceshi Chen, Guoqiang Chen, Yanxin Li, Haizhong Feng · 2021 · Advanced Science